Company: OncoMed Pharmaceuticals
Based: Redwood City, CA
Investors: Morgenthaler Ventures, Undisclosed Venture Firm, Bay Partners, Latterell Venture Partners, Vertical Group, The Nomura International, GSK Ventures, Adams Street Partners, De Novo Ventures, U.S. Venture Partners, Undisclosed Firm.
Scoop: OncoMed Pharmaceuticals is targeting cancer by developing monoclonal antibodies that target the biologic pathways critical to tumor initiating cells. The bulk of OncoMed's 2008 haul came from a massive $93.3 million round in November. It will be used to advance the company's cancer stem cell antibody programs--including lead compound OMP-21M18 and a second antibody--through Phase II clinical trials. OncoMed was a 2008 Fierce 15 company.